Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

The global prothrombin complex concentrates market is on a strong upward trajectory, with projections indicating substantial growth in the coming decade. According to a recent report by Future Market ...

Illustration from a crystal structure of the coagulation factor thrombin inhibited by two drug–peptide nucleic acid (PNA) molecules (pink and purple) bound together by base pairing; a PNA ...

Here we examine whether differences thrombin generation are associated with unfavourable outcome in thrombolysis treated patients with acute ischemic stroke. Methods: Two cohorts of patients with ...

Sturtevant, J. M., Laskowski, jun., M., Donnelly, T. H., and Scheraga, H. A., J. Amer. Chem. Soc., 77, 6168 (1955).

Center for Advanced Analytical Science, Guangzhou Key Laboratory of Sensing Materials and Devices, Guangdong Engineering Technology Research Center for Sensing Materials and Devices, School of ...

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-5127, United States ...

Recent studies have shown that NETs have procoagulant activity, wherein cfDNA triggers thrombin generation through activation of the intrinsic pathway of coagulation. We have recently shown that ...

Thrombin, generated during coagulation could disrupt endothelial barrier integrity through protease-activated receptor 1 (PAR1). Our previous study found that sphingosine-1-phosphate (S1P) contributed ...